Die Therapie der idiopathischen Lungenfibrose - was bleibt?

Literatur

• 1 Bjoraker J A, Ryu J H, Edwin M K. et al . Prognostic significance of histopathologic subsets in idiopathic pulmonary fibrosis.  Am J Respir Crit Care Med. 1998;  157 199-203
• 2 Flaherty K R, Toews G B, Travis W D. et al . Clinical significance of histological classification of idiopathic interstitial pneumonia.  Eur Respir J. 2002;  19 275-283
• 3 Travis W D, King T E, Bateman E D. et al . ATS/ERS international multidisciplinary consensus classification of idiopathic interstitial pneumonias. General principles and recommendations.  Am J Respir Crit Care Med. 2002;  165 277-304
• 4 Selman M, King Jr T E, Pardo A. Idiopathic pulmonary fibrosis: prevailing and evolving hypotheses about its pathogenesis and implication for therapy.  Ann Intern Med. 2001;  134 136-151
• 5 Ziesche R, Hofbauer E, Wittmann K. et al . A preliminary study of long-term treatment with interferon-γ-1b and low-dose prednisolone in patients with idiopathic pulmonary fibrosis.  N Engl J Med. 1999;  341 1264-1269
• 6 Prasse A, Müller K M, Kurz C. et al . Does interferon-γ improve pulmonary function in idiopathic pulmonary fibrosis?.  Eur Respir J. 2003;  22 906-911
• 7 Honoré I, Nunes H, Groussard O. et al . Acute respiratory failure after interferon-γ-therapy of end-stage pulmonary fibrosis.  Am J Respir Crit Care Med. 2003;  167 953-957
• 8 Raghu G, Brown K K, Bradford W Z. et al . A placebo-controlled trial of interferon-γ-Ib in patients with idiopathic pulmonary fibrosis.  N Engl J Med. 2004;  350 125-133
• 9 Behr J, Mayer K, Degenkolb B. et al . Antioxidative and clinical effects of high-dose N-acetylcysteine in fibrosing alveolitis.  Am J Respir Crit Care Med. 1997;  156 1897-1901